Literature DB >> 19085067

Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment.

Y H Hwang1, M S Kim, I B Song, J H Lim, B K Park, H I Yun.   

Abstract

We investigated the effects of hepatic and renal impairment on the pharmacokinetics of enrofloxacin in Sprague-Dawley rats. Experimental hepatic and renal failure were induced by carbon tetrachloride (CCL(4)) and 5/6 nephrectomy, respectively. After intravenous dosing of enrofloxacin (10 mg/kg), plasma concentrations of enrofloxacin were measured using liquid chromatograph/mass spectrometry. There was no significant effect of hepatic impairment on enrofloxacin pharmacokinetics. However, renal impairment markedly prolonged elimination half life (t(1/2lambdaz)) of enrofloxacin (P < 0.05), comparing with respective control. Total body clearance (Cl(b)) and volume of distribution at steady state (V(ss)) were significantly decreased (P < 0.05) by renal impairment. In conclusion, these results suggested that renal impairment could affect the pharmacokinetics of enrofloxacin.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19085067     DOI： 10.1007/s11259-008-9195-y

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN： 0165-7380            Impact factor:   2.459


  23 in total

1.  Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows.

Authors:  M A Bregante; P Saez; J J Aramayona; L Fraile; M A Garcia; C Solans
Journal:  Am J Vet Res       Date:  1999-09       Impact factor: 1.156

2.  Enrofloxacin-associated retinal degeneration in cats.

Authors:  K N Gelatt; A van der Woerdt; K L Ketring; S E Andrew; D E Brooks; D J Biros; H M Denis; T J Cutler
Journal:  Vet Ophthalmol       Date:  2001-06       Impact factor: 1.644

3.  Allometric analysis of ciprofloxacin and enrofloxacin pharmacokinetics across species.

Authors:  S K Cox; M B Cottrell; L Smith; M G Papich; D L Frazier; J Bartges
Journal:  J Vet Pharmacol Ther       Date:  2004-06       Impact factor: 1.786

4.  The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease.

Authors:  E M Jones; C M McMullin; A J Hedges; A M Lovering; L O White; D S Reeves; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

5.  Pharmacokinetics of enrofloxacin after intravenous and intramuscular administration in Angora goats.

Authors:  M Elmas; B Tras; S Kaya; A L Bas; E Yazar; E Yarsan
Journal:  Can J Vet Res       Date:  2001-01       Impact factor: 1.310

Review 6.  Pharmacokinetics of quinolones in renal insufficiency.

Authors:  J P Fillastre; A Leroy; B Moulin; M Dhib; F Borsa-Lebas; G Humbert
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

7.  In vitro dose-dependent effects of enrofloxacin on equine articular cartilage.

Authors:  L A Beluche; A L Bertone; D E Anderson; C W Kohn; S E Weisbrode
Journal:  Am J Vet Res       Date:  1999-05       Impact factor: 1.156

8.  Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure.

Authors:  K Naora; N Ichikawa; H Hirano; K Iwamoto
Journal:  J Pharm Pharmacol       Date:  1999-05       Impact factor: 3.765

9.  Effects of fluoroquinolone antimicrobials alone and in conjunction with theophylline on seizures in amygdaloid kindled rats. Mechanistic and pharmacokinetic study.

Authors:  P M Vancutsem; W S Schwark
Journal:  Epilepsy Res       Date:  1992-10       Impact factor: 3.045

10.  Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones.

Authors:  R A Blum
Journal:  Am J Med       Date:  1992-04-06       Impact factor: 4.965
View more
  1 in total

1.  Human Food Safety Implications of Variation in Food Animal Drug Metabolism.

Authors:  Zhoumeng Lin; Christopher I Vahl; Jim E Riviere
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.